Dr. Jeffrey Cummings presents potential new therapy in dementia
CALGARY, Alberta and SHANGHAI, Sept. 04, 2018 (GLOBE NEWSWIRE) -- As a follow up to its July 17, 2018 news release, Resverlogix Corp. (“Resverlogix” or the “Company”) (RVX:TSX) announced today that it has presented at the first Clinical Trials in Alzheimer’s Disease (CTAD) Asia conference in Shanghai, China, this past weekend. Dr. Jeffrey Cummings, Founding Director of the Cleveland Clinic Lou Ruvo Brain Health Center, Las Vegas, Nevada, delivered a keynote presentation on the design and baseline characteristics of a pre-specified substudy of cognition in elderly patients in the Company’s ongoing Phase 3 BETonMACE clinical trial. In addition, a poster presentation highlighted potential Mechanism of Action of apabetalone in addressing vascular dementia.
"Apabetalone has the potential to confirm a new hypothesis of BET inhibition and its impact on vascular cognitive impairment (VCI), dementia and Alzheimer’s disease,” stated Dr. Cummings. “These new and previously reported data on impact in the biological areas of neuro inflammation and complement biology potentially provide us a new approach for the millions of patients with VCI, dementia and Alzheimer’s patients.”
Proteomics from the Company’s Phase 2 ASSURE clinical trial highlighted proteins linked to cognitive decline and neurodegenerative disease favourably affected by apabetalone treatment, including but not limited to ATP5O, HSPD1, APP, HSP90AB1, HSP90AA1, HSPA8, ANXA1, EEF1B2, RTN4R, ATP5B and APCS (p<0.05). These serum proteins have been reported to play a potential role in impacting neuro plasticity, blood brain barrier integrity and mitochondrial function, all reported risk markers for neurodegeneration. The Company will continue its pursuit in further elucidating these and other proteins that are known to drive neurovascular risk.
Resverlogix intends to present further data from its Phase 3 BETonMACE clinical trial at upcoming conferences to continue to build on the potential of BET inhibition and establish awareness of this novel approach for vascular cognitive impairment and dementia.
BETonMACE is a Phase 3 cardiovascular event outcomes trial in approximately 2,425 high-risk cardiovascular patients with type II diabetes mellitus. A pre-specified subpopulation in the trial is comprised of patients 70 years of age and over. For this patient cohort, Resverlogix is performing the Montreal Cognitive Assessment (“MoCA”) at Baseline, week 52, week 104 and at the end of the trial. Approximately 450 patients will be assessed in this whole group of which approximately half have a MoCA of ≤25, deemed to have mild cognitive impairment.
The BETonMACE trial is expected to be complete by the end of 2018 with the topline results expected shortly thereafter.
Resverlogix is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra-terminal) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with high-risk cardiovascular disease, diabetes mellitus, chronic kidney disease, end-stage renal disease treated with hemodialysis, neurodegenerative disease, Fabry disease, peripheral artery disease and other orphan diseases, while maintaining a well described safety profile.
Resverlogix common shares trade on the Toronto Stock Exchange (TSX:RVX).
Follow us on Twitter: @Resverlogix_RVX
For further information please contact:
This news release may contain certain forward-looking information as defined under applicable Canadian securities legislation, that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts" and other similar expressions. In particular, this news release includes forward looking information relating to, and the potential role of apabetalone in the treatment of CVD, DM, chronic kidney disease, end-stage renal disease treated with hemodialysis, neurodegenerative disease, Fabry disease, peripheral artery disease and other orphan diseases. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous assumptions and risk factors including those discussed in our Annual Information Form and most recent MD&A which are incorporated herein by reference and are available through SEDAR at www.sedar.com. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement and are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.